Research institution
The First Affiliated Hospital of Xiamen University Clinical Trials
Studies where The First Affiliated Hospital of Xiamen University is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 67Prostate Cancer (Diagnosis), ACP3
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
This study aims to evaluate the feasibility, safety, and diagnostic performance of 68Ga-XMFH01, a novel ACP3-targeted dual-modality PET and fluorescence imaging probe, for preoperative PET/CT imaging and intraoperative…
- Conditions
- Prostate Cancer (Diagnosis), ACP3, PET / CT
- Trial name
- NCT07885423
- Testing
- 68Ga-XMFH01 PET/CT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Hematologic Disease
Study of Anxiety and Depression in Patients With Hematologic Malignancies
Assessment of Anxiety and Depression Status in Patients with Hematologic Malignancies
- Trial name
- NCT07883070
- Testing
- Baseline Anxiety and/or Depression
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Solid Tumor (Excluding CNS), HER2
68Ga-XHER2 PET/CT for HER2 Assessment
The objective of this study is to evaluate the feasibility of 68Ga-XHER2 PET/CT as a noninvasive imaging approach for assessing HER2 expression in patients with solid tumors and to investigate the correlation between tracer…
- Conditions
- Solid Tumor (Excluding CNS), HER2, PET / CT
- Trial name
- NCT07885436
- Testing
- 68Ga-XHER2 PET/CT
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
DLL3-expressing Tumors, PET / CT
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
The objective of the study is to evaluate the diagnostic value of DLL3-targeted PET/CT in patients with suspected or histologically confirmed neuroendocrine carcinoma, and to compare with conventional imaging modalities.
- Conditions
- DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
- Trial name
- NCT07458906
- Testing
- Diagnostic Test: conventional imaging (CT, MRI or 18F-FDG PET/CT), DLL3-targeted PET/CT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Hypertension
A Prospective Nurse Cohort Study in Xiamen, China
The Nurse Cohort Study Xiamen (NCSX) is an open-ended prospective cohort study with very broad research aims. The primary objectives of the NCSX is planned to examine genetic, epigenetic, biological, psychological, social…
- Trial name
- NCT03799653
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Hepatocellular Carcinoma (HCC), Glypican-3
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.
- Conditions
- Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
- Trial name
- NCT07677774
- Testing
- GPC3-targeted PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Nasopharyngeal Carcinoma (NPC), PET / CT
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
This is an observational cohort study designed to (1) evaluate whether Gallium-68 (68Ga)-labeled fibroblast activation protein inhibitor ligand LM3 (68Ga-FAPI-LM3) positron emission tomography/computed tomography (PET/CT)…
- Trial name
- NCT07137052
- Where
- China
- Volunteers
- 732 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Relapsed or Refractory Acute Myeloid Leukemia
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
- Trial name
- NCT07783100
- Testing
- venetoclax, chidamide, and chiglitazar sodium (VCC)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell…
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line
- Trial name
- NCT07778212
- Testing
- Orelabrutinib Combined with Pola-R-CHP Regimen
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Tumor, Solid Tumor
Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer
In this study, we comprehensively evaluated the clinical utility of Trop2 PET/CT (68Ga-MY6349 PET/CT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET/CT.
- Conditions
- Tumor, Solid Tumor, Thyroid Cancer
- Trial name
- NCT07753499
- Testing
- Compared the diagnostic performance of 68Ga-MY6349 PET/CT with 68Ga-FAPI PET/CT
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Xiamen University